Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > looks to me

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Apr 19, 2021 7:25pm

199 Views

Post# 33026553

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:looks to me

seems like 10 months out every 10 months. I was told 10 months out 10 months ago and same before that. Seems no interest or they value too high when can't convince market or pharma of the value and must go alone.

WalkOverTheStrt wrote: Marky -

"He mentioned on a number of occasions that negotiation for OTENA are underway and there could be partnerships over the next 10 months"

Do you think Dan was hedging their bets on partnership discussions timeline? April +10 months be Feb - i.e. 20 months post pH2B results.

01 June PH2B results provided.
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/antibe-therapeutics-announces-positive-top-line-data-from-phase-2b-dose-ranging-efficacy-study-for-atb-346